Mirae Asset Capital Life Science的动态

Ever heard of sarcoma? Sarcoma is a rare form of cancer that originates in bones and soft tissues, such as fat and blood vessels. In the United States, approximately 15,000 new cases are diagnosed each year. Understanding sarcoma is vital for its early detection and effective treatment strategies. ???? ?? Medcare Pharma: Your Way to Cure Contact us: ?? | 1-866-4-MEDICINE ?? | [email protected] ?? | https://lnkd.in/gA9pPUVR #CancerAwareness #SarcomaFacts #clinicaltrial #clinicalresearch #medicalresearch #clinicalstudies #clinicalstudy #healthcare #medcarepharma #researchstudies

China’s National Medical Products Administration has approved a new treatment combination for patients with locally advanced or metastatic #UrothelialCancer. Investigated in partnership with Pfizer and Merck, we’re bringing new hope to patients living with hard-to-treat cancers. Read more:? https://lnkd.in/gHpahxNG #ScienceFirstForPatients #ChangingTomorrow?

?? The phase 2 LITESPARK-003 study has shown that the HIF-2α inhibitor #belzutifan combined with #cabozantinib for treatment-naive patients with advanced clear-cell #RCC can provide promising antitumor activity:

CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

?? A new study published is lending critical insights into patient perspectives on treatment-related toxicities and therapeutic drug monitoring with TKIs for the treatment of NSCLC. ?? Learn more: https://buff.ly/41vsMyP #NSCLC #lcsm

$MRK: Keytruda injection proves as effective as the approved IV version in trials, offering patients a potentially more convenient treatment option. A promising advancement in cancer care: https://ibn.fm/XaIbb #Merck #Keytruda #CancerTreatment #Pharma #Innovation

The oral chemotherapy drug CFI-400945 is effective against homologous recombinant deficient uterine leiomyosarcoma. Enhanced DNA double-strand breaks is significantly more in BRCA2-KO cells than in WT cells (γH2AX immunofluorescent staining. γH2AX (red); Hoechst 33,342 (blue); and α-tubulin (green). DNA damage induced by CFI-400945 is not repaired either by HR or NHEJ in BRCA2-KO. https://lnkd.in/dg6xv66F

Preemptive DPYD PGx testing helps healthcare providers identify chemotherapy patients at risk of developing severe toxicity from fluoropyrimidine treatment. The chemotherapy drug fluorouracil (5-FU), or capecitabine, is commonly used for treatment of solid cancers such as breast, colorectal, lung and other malignancies. While most patients tolerate these drugs well, some patients can experience life-threatening toxicities. DPYD PGx testing is a simple and effective way to maximize the benefits of chemotherapy while minimizing the risk of severe adverse events. Read more about the benefits of DPYD testing here: https://lnkd.in/gPYcXCVY #patientsafety #DPYD #5FU #capecitabine #pgx #pharmacogenetics #precisionprescribing

Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

New insights into Parkinson's disease (PD) therapy by Olga Ivanova! This study shows anti-αSyn immunotherapy reduces αSyn aggregation in PD models, with microglial activation being a key target for treatment. Could this be the future of PD therapeutics? #PSPjournal #ASCPTjournals #ClinicalPharmacology #Parkinsonsdisease Check it out here: https://bit.ly/3TFbkTO